Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Clinical Research Center for Medicine, International University of Health and Welfare, Center for Brain and Cerebral Vessels, Sanno Medical Center, Tokyo, Japan.
Cerebrovasc Dis Extra. 2024;14(1):158-164. doi: 10.1159/000541703. Epub 2024 Oct 4.
Stroke burden is largely due to long-term impairments requiring prolonged care and loss of productivity. We aim to identify and assess studies of different registered pharmacological therapies as treatments for improving post-stroke impairments and/or disabilities.
In a systematic search and review (PROSPERO registration: CRD42022376973), studies of treatments that have been investigated as recovery-enhancing or recovery-promoting treatments in adult patients who had suffered a stroke will be searched for, screened, and reviewed based on the following: participants (P): adult humans, aged 18 years or older, diagnosed with stroke; interventions (I): registered or marketed pharmacological therapies that have been investigated as recovery-enhancing or recovery-promoting treatments in stroke; comparators (C): active or placebo or no comparator; outcomes (O): stroke-related neurological impairments and functional/disability assessments. Data will be extracted from included papers, including patient demographics, study methods, keystroke inclusion criteria, details of intervention and control, and the reported outcomes.
"The best available studies" based on study design, study size, and/or date of publication for different therapies and stroke subtypes will be selected and graded for level of evidence by consensus.
There are conflicting study results of pharmacological interventions after an acute stroke to enhance recovery. This systematic search and review will identify the best evidence and knowledge gaps in the pharmacological treatment of post-stroke patients as well as guide clinical decision-making and planning of future studies.
中风负担在很大程度上是由于长期的损伤导致需要长期护理和生产力损失。我们旨在确定和评估不同已注册的药理学治疗方法作为改善中风后损伤和/或残疾的治疗方法的研究。
在系统的搜索和综述（PROSPERO 注册：CRD42022376973）中，将搜索、筛选和审查已被调查为成人中风患者恢复增强或促进恢复的治疗方法的治疗研究，基于以下内容：参与者（P）：年龄在 18 岁或以上，被诊断为中风的成年人；干预措施（I）：已被调查为中风恢复增强或促进恢复的治疗方法的已注册或市售药理学治疗方法；对照措施（C）：活性或安慰剂或无对照；结局（O）：与中风相关的神经损伤和功能/残疾评估。将从纳入的论文中提取数据，包括患者人口统计学、研究方法、关键纳入标准、干预和对照的详细信息以及报告的结局。
将根据研究设计、研究规模和/或不同疗法和中风亚型的发表日期选择“最佳现有研究”，并通过共识对证据水平进行分级。
急性中风后增强恢复的药理学干预存在相互矛盾的研究结果。这项系统的搜索和综述将确定中风后患者的药理学治疗的最佳证据和知识空白，并指导临床决策和未来研究的规划。
